Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 5/20 | 0.48 |
| ▸ | GSR | P00390 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28460738 | 0.88 | MAPT (0.43) | TXNRD1GSRMAPTMERTKL3MBTL1 | |
| SCHEMBL963587 | 0.85 | TXNRD1 (0.47) | TXNRD1GSRMAPTMERTKL3MBTL1 | |
| SCHEMBL27913490 | 0.84 | TXNRD1 (0.39) | TXNRD1GSRMAPTMERTKL3MBTL1 | |
| SCHEMBL9136449 | 0.83 | CTSB (0.45) | TXNRD1MAPTL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL16469858 | 0.82 | MAPT (0.42) | TXNRD1GSRMAPTMERTKL3MBTL1 | |
| SCHEMBL937505 | 0.81 | MERTK (0.49) | TXNRD1GSRMAPTMERTKL3MBTL1 | |
| SCHEMBL29990867 | 0.81 | MERTK (0.49) | TXNRD1GSRMAPTMERTKL3MBTL1 | |
| SCHEMBL29064672 | 0.80 | TXNRD1 (0.37) | TXNRD1GSRMAPTMERTKL3MBTL1 | |
| SCHEMBL16470360 | 0.80 | TXNRD1 (0.37) | TXNRD1GSRMAPTMERTKL3MBTL1 | |
| SCHEMBL2474647 | 0.78 | TXNRD1 (0.56) | TXNRD1GSRMAPTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003865-A1 | NOVEL 2-DIETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-20110003865-A1 | NOVEL 2-DIETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-20110003865-A1 | NOVEL 2-DIETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| EP-2231608-A1 | NOVEL 2-DIETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NeuroSearch A/S (DK) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074592-A1 | NOVEL 2-DIETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074592-A1 | NOVEL 2-DIETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003865-A1 | NOVEL 2-DIETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | KCNA7, KCNN3, KCNJ2 | TXNRD1 2566/4885GSR 2561/4885MAPT 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.